Pfizer, Bayer-backed Pyxis ups IPO price as biotech's public run continues unabated

As a barometer of the rude health biotechs continue to find themselves in on Wall Street, Big Pharma-backed oncology player Pyxis Oncology is upping its IPO.

Having last month initially asked for the now standard $100 million IPO, the Cambridge, Massachusetts-based biotech has boosted that to $143 million by offering 9.5 million shares at a price range of $14 to $16, nabbing 14% more in proceeds than previously anticipated. according to Renaissance Capital.